Proniras Corporation is a Seattle-based biopharmaceutical company focused on developing tezampanel as a medical countermeasure for nerve agent-induced seizures. The development of tezampanel in this indication is being funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800008C.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/27/18 | undisclosed |
Accelerator Life Science Partners Alexandria Real Estate Equities ARCH Venture Partners Eli Lilly and Company Johnson & Johnson Innovation Watson Fund WRF Capital WuXi AppTec | undisclosed | |
| 02/01/24 | $4,650,000 | Series B |
Accelerator Life Science Partners ARCH Venture Partners Watson Fund WRF Capital | undisclosed |
